Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study
Open Access
- 13 February 2025
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (2) , e0143524
Abstract
This study aimed to describe the population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation (ECMO) and to identify dosing regimens with a high likelihood of achieving effective exposures. Serial blood samples were collected over a single-dosing interval during ECMO. Total plasma concentrations were measured by a validated chromatographic assay. A population pharmacokinetic model was built and Monte Carlo dosing simulations were performed using Monolix. The probability of target attainment (PTA) and fractional target attainment (FTA) rates were simulated for various caspofungin dosing regimens against Candida albicans , Candida glabrata , and Candida parapsilosis . In all, 64 plasma concentration-time points were obtained from 8 critically ill patients receiving ECMO. Plasma concentration-time data for caspofungin were best described by a one-compartment model with first-order elimination. Lean body weight was identified as a significant covariate of volume of distribution. The typical volume of distribution and clearance of caspofungin in this cohort were 8.13 L and 0.55 L/h, respectively. The licensed caspofungin dosing regimen (a loading dose of 70 mg on day 1 followed by a maintenance dose of either 50 mg/day or 70 mg/day) demonstrated optimal PTA rates (≥90%) against C. albicans with an MIC of ≤0.064 mg/L, C. glabrata with an MIC of ≤0.125 mg/L, and C. parapsilosis with an MIC of ≤0.064 mg/L. The FTA analysis suggested that the licensed dosing regimen is only optimal (≥95%) against Candida glabrata , regardless of lean body weight. A higher-than-standard empirical dosing regimen (e.g., a loading dose of 100 mg on day 1, followed by a maintenance dose of 100 mg daily) is likely advantageous for critically ill patients receiving ECMO.Keywords
Funding Information
- The Prince Charles Hospital Research Foundation
- Australian and New Zealand College of Anaesthetists
- Advanced Pharmacy Australia
- DHAC | National Health and Medical Research Council
This publication has 47 references indexed in Scilit:
- Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort StudyClinical Pharmacokinetics, 2021
- Caspofungin pharmacokinetics and probability of target attainment in ICU patients in ChinaJournal of Global Antimicrobial Resistance, 2021
- How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)Clinical Microbiology and Infection, 2020
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#Intensive Care Medicine, 2020
- Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltrationInternational Journal of Antimicrobial Agents, 2018
- CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance ProgramInternational Journal of Antimicrobial Agents, 2017
- Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or HaemodiafiltrationClinical Pharmacokinetics, 2016
- Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal ExposureClinical Pharmacokinetics, 2015
- Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill PatientsJAMA, 2001
- Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patientsEuropean Journal of Clinical Pharmacology, 1983